Our problem imo was the skill level of the teams who wanted leronlimab. Look at the 90 day survival from RLFTF's drug. It was 36 vs 37. And that was being run by NIH and at a time when teams had learned how to treat patients and had more options. We were just n the 80s at the craziest time in the pandemic, but so was placebo. Our docs were on the cutting edge of treatment.
News 
Market Data 
Discover 
AI
